Table 5.

Potential risk factors of complications in pregnancies with SLE.

	Maternal Complications
	Univariate Analysis			Multivariate Analysis
	OR	95% CI	P	OR	95% CI	P
Hemoglobin < 10 g/dL	17.7	3.63–86.25	< 0.001^{^*}	4.38	0.4–47.71	0.18
Thrombocytopenia	3.3	1.23–8.85	0.024^{^*}	2.12	0.46–9.61	0.34
C3 < 90 mg/dL + C4 < 10 mg/dL	4.41	1.9–10.26	< 0.001^{^*}	1.56	0.48–5.03	0.47
Anti-dsDNA Ab positivity	2.38	1.12–5.03	0.02^{^*}	0.86	0.25–2.94	0.81
Proteinuria > 0.5 g/d	9.82	3.61–26.7	< 0.001^{^*}	7.25	1.75–30.05	0.008^{^*}
SLEDAI-2K, at pregnancy > 4	4.61	2.08–10.23	< 0.001^{^*}	0.7	0.18–2.77	0.61
LLDAS	0.09	0.03 - 0.22	< 0.001^{^*}	0.18	0.04–0.74	0.016^{^*}
Cumulative steroid dose after diagnosis > 3500 mg	7.81	3.14–19.39	< 0.001^{^*}	3.99	1.25–12.77	0.024^{^*}
Mean steroid dose during pregnancy > 6 mg/d	6.63	2.95–14.89	< 0.001^{^*}	1.78	0.53–5.94	0.36
History of CYC treatment	6.33	2.52–15.88	< 0.001^{^*}	2.7	0.66–11.03	0.18

	Fetal complications
	Univariate analysis			Multivariate analysis
	OR	95% CI	P	OR	95% CI	P
Hemoglobin < 10 g/dL	5.91	1.23–28.29	0.029^{^*}	1.56	0.15–16.87	0.71
Thrombocytopenia	7.77	2.16–27.89	< 0.001^{^*}	18.42	2.09–162.63	0.009^{^*}
C3 < 90 mg/dL + C4 < 10 mg/dL	4.66	1.93–11.24	< 0.001^{^*}	4.57	1.46–14.33	0.017^{^*}
Anti-dsDNA Ab positivity	2.53	1.29–4.99	0.013^{^*}	1	0.36–2.784	0.99
Proteinuria > 0.5 g/d	3.71	1.37–10.09	0.01^{^*}	0.94	0.24–4.77	0.94
SLEDAI-2K, at pregnancy > 4	9.63	4.06–22.8	< 0.001^{^*}	2.93	0.75–11.5	0.004^{^*}
LLDAS	0.14	0.07–0.29	< 0.001^{^*}	0.21	0.06–0.65	0.01^{^*}
Mean steroid dose during pregnancy > 6 mg/d	3.59	1.63–7.92	0.035^{^*}	0.98	0.15–1.75	0.28

↵^*P < 0.05. Ab: antibody; CYC: cyclophosphamide; LLDAS: Lupus Low Disease Activity State; SLE: systemic lupus erythematosus; SLEDAI-2K: SLE Disease Activity Index 2000.